Short-term triple therapy for Hp -positive duodena

e707004304

Short-term triple therapy for Hp-positive duodenal ulcer efficacy

Key words short-term triple therapy for duodenal ulcer Hp gastric acid, pepsin digestion and Helicobacter pylori (Hp ) infection is the most important risk factors of peptic ulcer, inhibit gastric acid secretion and eradication of Hp the treatment of peptic ulcer and prevention of ulcer recurrence major initiatives. 4 weeks of conventional therapy, the proton pump inhibitor (PPI) and the combination of amoxicillin and clarithromycin 1 week to continue PPI 3 weeks, and omeprazole as the PPI representative of drugs, the treatment of peptic ulcer has been recognized. This study aimed to investigate the short-term esomeprazole triple therapy for Hp-positive duodenal ulcer. 1 clinical data 1.1 General information on the inclusion criteria: age ≥ 18 years, endoscopy confirmed active duodenal ulcer (ulcer diameter of 3 ~ 20mm, 1 ~ 2 个), Hp testing positive (rapid urease test strongly positive). Exclusion criteria: age <18 years old, complex ulcer, pyloric obstruction or a combination of active bleeding, liver and kidney with severe heart and lung disease, are taking non-steroidal drugs, 1 month oral administration of anti-Hp used drugs, penicillin allergy, pregnancy or lactating women, esophagus, stomach, duodenum surgery, cancer and alcoholism. Select January 2004 to December 2005 60 cases of duodenal ulcer eligible, randomly divided into study group and treatment group, 30 cases in each. Basic differences between the two groups were not significant, both in the gastric mucosa of Endoscopic Biopsy 2 to 3, by rapid urease test, 3d medication started within 6 weeks, repeated endoscopy and urease breath test investigation (14C- UBT), measured values <100dpm> 50% reduction in the number or ulcers; invalid: ulcer size reduction or no change and increase. Healing rate of the first two terms, the first three terms efficient. Gastrointestinal symptoms rating: none (asymptomatic feeling); mild (aware of symptoms, but does not affect the normal activities); moderate (clearly does not affect the normal life); severe (loss of function, inability to carry out normal activities) . Remission after treatment for more than a relief of symptoms, the cure for the symptoms disappeared, improved to alleviate the symptoms, not invalid as to reduce the symptoms. 1.4 Application of SPSS 10.0 statistical software, data using χ2 test. To P <0.05 as significant difference. Were not lost into the statistics. 2 results of 2 patients in each group lost to follow-up rate of 93.3%. Ulcer healing rate study group 89.3% (25/2 Cool

, control group 85.7% (24/2 Cool

, the difference was not significant; ulcer study group was 92.9% efficient (26/2 Cool

, control group 92.9% (26/2 Cool

the difference was not statistically significant; Hp eradication rates of group 92.9% (26/2 Cool

, control group 89.3% (25/2 Cool

, the difference was not significant. Treatment of gastrointestinal symptoms after 1 week of evaluation, two groups of patients with abdominal pain, back acid and heartburn and other symptoms were in remission after medication 7d, respectively, on the incidence of abdominal pain before treatment of 100% and 92.9% to 7.1% and 10.7% , acid reflux rates were decreased from 53.6% and 57.1% to 10.7% and 7.1%, the incidence of heartburn before treatment respectively 67.9% and 71.4% dropped to 0, no significant difference between two groups.